Dendritic cell (DC)-based
vaccines are recognized as a promising immunotherapeutic strategy against
cancer. Various adjuvants are often incorporated to enhance the modest immunogenicity of DC
vaccines. More specifically, many of the commonly used adjuvants are derived from bacteria. In the current study, we evaluate the use of apoptosis inhibitor 5 (API5), a damage-associated molecular pattern expressed by many human
cancer cells, as a novel DC
vaccine adjuvant. We showed that API5 can prompt activation and maturation of DCs and activate NFkB by stimulating the
Toll-like receptor signaling pathway. We also demonstrated that vaccination with API5-treated DCs pulsed with OVA, E7, or AH1-A5
peptides led to the generation of OVA, E7, or AH1-A5-specific CD8 + T cells and memory T cells, which is associated with long term
tumor protection and antitumor effects in mice, against EG.7, TC-1, and CT26
tumors. Additionally, we determined that API5-mediated DC activation and immune stimulation are dependent on TLR4. Lastly, we showed that the API5
protein sequence fragment that is proximal to its leucine zipper motif is responsible for the adjuvant effects exerted by API5. Our data provide evidence that support the use of API5 as a promising adjuvant for DC-based
therapies, which can be applied in combination with other
cancer therapies. Most notably, our results further support the continued investigation of human-based adjuvants.